F-star Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

F-star Therapeutics (NASDAQ: FSTX) announced participation in two virtual conferences: the H.C. Wainwright Global Life Science Conference on March 9, 2021, and the Oppenheimer & Co 31st Annual Healthcare Conference on March 17, 2021. CEO Eliot Forster will lead fireside chats at both events, detailing the company's business strategy and updates on its clinical programs, particularly FS120 and FS222, which target CD137. These next-generation immunotherapies aim to enhance cancer treatment.

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that the company’s management team will participate in the H.C. Wainwright Global Life Science Conference and the Oppenheimer & Co 31st Annual Healthcare Conference. Both events will take place virtually.

Details are as follows:

H.C. Wainwright Global Life Science Conference (March 9-10, 2021)

Fireside chat with F-star CEO, Eliot Forster

Date: March 9, 2021

Time: 7:00am EST

Oppenheimer & Co 31^st Annual Healthcare Conference (March 16-18, 2021)

Fireside chat with F-star CEO, Eliot Forster

Date: March 17, 2021

Time: 8:00am EST

Replay will be available at: https://wsw.com/webcast/oppenheimer9/fstar/2958208 for 90 days following the conference.

Eliot Forster, CEO of F-star Therapeutics, Inc., said: “It has been a busy start to the year, having listed on NASDAQ at the end of 2020, and we look forward to sharing our business strategy and updates on our four clinical programs. We are particularly looking forward to presenting our most recent updates on FS120 and FS222 (both targeting CD137). These two programs, and our other next-generation immunotherapies, have significant potential to transform the lives of patients with cancer.”

About F-star Therapeutics, Inc.

F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific natural antibody (mAb²™) format, F-star’s mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability. For more information visit www.f-star.com and follow us on LinkedIn and Twitter.

For further information, please contact:

For investor inquiries
Lindsey Trickett
VP Investor Relations & Communications
+1 240 543 7970
lindsey.trickett@f-star.com

For media inquiries
Helen Shik
Shik Communications LLC
617-510-4373
Shik.Helen10@gmail.com

FAQ

When will F-star Therapeutics participate in the H.C. Wainwright Global Life Science Conference?

F-star Therapeutics will participate in the H.C. Wainwright Global Life Science Conference on March 9, 2021.

What is the date and time of F-star Therapeutics' fireside chat at the Oppenheimer Conference?

The fireside chat will take place on March 17, 2021, at 8:00 am EST.

What updates will F-star Therapeutics share at the upcoming conferences?

F-star Therapeutics will share updates on its business strategy and its clinical programs, especially FS120 and FS222.

What does F-star Therapeutics specialize in?

F-star Therapeutics specializes in developing next-generation immunotherapies for cancer treatment.

What is the significance of FS120 and FS222 for F-star Therapeutics?

FS120 and FS222 target CD137 and are expected to play a critical role in transforming cancer therapy.